53292-89-0

Basic information

• Product Name: BOC-1,4-TRANS-ACHC-OH
• Synonyms: RARECHEM AR PA 0013;TRANS-4-TERT-BUTOXYCARBONYLAMINOCYCLOHEXANECARBOXYLIC ACID;TRANS-4-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;TRANS-1-(T-BUTYLOXYCARBONYLAMINO)CYCLOHEXYL-4-CARBOXYLIC ACID;TRANS-1-(TERT-BUTYLOXYCARBONYL-AMINO)-CYCLOHEXYL-4-CARBOXYLIC ACID;BOC-1,4-TRANS-ACHC-OH;BOC-TRANS-1,4-AMINOCYCLOHEXANE CARBOXYLIC ACID;BOC-TRANS-4-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID
• CAS NO: 53292-89-0
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• Product Categories: Alicyclic Amino Acids;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 53292-89-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 181.0 to 185.0 °C
• Boiling Point: 396.7 °C at 760 mmHg
• Flash Point: 193.7 °C
• Appearance: White/Powder
• Density: 1.13 g/cm³
• Vapor Pressure: 2.12E-07mmHg at 25°C
• Refractive Index: 1.493
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform, Methanol (Slightly)
• PKA: 4.76±0.10(Predicted)
• BRN: 7641071
• CAS DataBase Reference: BOC-1,4-TRANS-ACHC-OH(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-1,4-TRANS-ACHC-OH(53292-89-0)
• EPA Substance Registry System: BOC-1,4-TRANS-ACHC-OH(53292-89-0)

Safety Data

• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 53292-89-0(Hazardous Substances Data)

Usage

Description

BOC-1,4-TRANS-ACHC-OH, also known as Boc-trans-4-aminocyclohexanecarboxylic acid, is a white solid reagent used in the synthesis of N-myristoyltransferase and CD38 inhibitors. It plays a crucial role in the development of pharmaceutical compounds targeting these enzymes, which are involved in various cellular processes and have potential therapeutic applications.

Uses

Used in Pharmaceutical Industry:
BOC-1,4-TRANS-ACHC-OH is used as a reagent for the synthesis of N-myristoyltransferase and CD38 inhibitors for their potential therapeutic applications in various diseases.
Used in Research and Development:
BOC-1,4-TRANS-ACHC-OH is used as a key compound in the research and development of novel inhibitors targeting N-myristoyltransferase and CD38 enzymes, contributing to the advancement of medical science and the discovery of new treatments for various conditions.
Used in Drug Synthesis:
BOC-1,4-TRANS-ACHC-OH is used as an essential building block in the synthesis of drugs that modulate the activity of N-myristoyltransferase and CD38, which can have implications in the treatment of various diseases and disorders related to these enzymes.

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-8(5-7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t8-,9-

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 38446-95-6 4-oxocyclohexanecarboxylic acid tert-butyl ester 
• 6297-22-9 4-carbomethoxycyclohexanone 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 881657-40-5 tert-butyl ((3R,6S)-6-formyltetrahydro-2H-pyran-3-yl)carbamate 
• 603130-12-7 1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol 
• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 1776-53-0 trans-4-aminocyclohexanecarboxylic acid 

Downstream Products

• 146307-51-9 methyl (1R,4R)-4-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylate 
• 400898-94-4 trans-(4-formylcyclohexyl)methylcarbamic acid tert-butyl ester 
• 400899-08-3 tert-butyl ((1r,4r)-4-(hydroxymethyl)cyclohexyl)(methyl)carbamate 
• 400899-07-2 methyl (1r,4r)‐4‐{[(tert‐butoxy)carbonyl](methyl)amino}cyclohexane‐1‐carboxylate 
• 400899-12-9 methyl-[4-(3-oxo-propyl)-cyclohexyl]-carbamic acid tert-butyl ester 
• 400899-11-8 [4-(3-hydroxy-propyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-10-7 3-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-propionic acid ethyl ester 
• 400899-16-3 [4-(5-hydroxy-pentyl)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 400899-17-4 methanesulfonic acid 5-[4-(tert-butoxycarbonyl-methyl-amino)-cyclohexyl]-pentyl ester 
• 878395-72-3 4-amino-cyclohexanecarboxylic acid [2-(cyclopentanecarbonyl-amino)-benzothiazol-6-yl]-amide 
• 216957-26-5 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)piperazine 
• 216957-35-6 ethyl 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)-2-piperazinecarboxylate 
• 757171-98-5 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(5-chloro-2H-benzopyran-3-sulfonyl)piperazine 
• 944404-27-7 [trans-4-(4-isopropyl-piperazine-1-carbonyl)-cyclohexyl]-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors

In this study, a series of novel hydroxyamidine derivatives were identified as potent and selective IDO1 inhibitors by structure-based drug design. Among them, compounds 13-15 and 18 exhibited favorable enzymatic and cellular activities. Compound 18 showed improved bioavailability in mouse, rat, and dog (F% = 44%, 58.8%, 102.1%, respectively). With reasonable in vivo pharmacokinetic properties, compound 18 was further evaluated in a transgenic MC38 xenograft mouse model. The combination of compound 18 with PD-1 monoclonal antibody showed a synergistic antitumor effect. These data indicated that compound 18 as a potential cancer immunotherapy agent should warrant further investigation.

BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

Small molecule stimulation of β-cell regeneration has emerged as a promising therapeutic strategy for diabetes. Although chemical inhibition of dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is sufficient to enhance β-cell replicat